LCM
AGRX

Laurion Capital Management’s Agile Therapeutics AGRX Stock Holding History

Laurion Capital Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-63
Closed -$233K – 1247
2020
Q1 		$233K Buy
+63
New +$362K ﹤0.01% 661

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
DCM
DG Capital Management New York $475M AUM 36.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Laurion Capital Management's AGRX Position: Q2 2020 in Review

Laurion Capital Management sold out of Agile Therapeutics (AGRX) in Q2 2020, closing a stake of 63 shares — an estimated $233K sold.

Laurion Capital Management first reported a position in AGRX in Q1 2020 and held it in 1 quarter. The position peaked at $233K in Q1 2020. 79 funds tracked by Wall St. Rank hold AGRX as of Q2 2020.

  • Laurion Capital Management reported no remaining Agile Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Laurion Capital Management sold 63 Agile Therapeutics shares in Q2 2020, an estimated $233K.
  • Laurion Capital Management first reported a position in Agile Therapeutics in Q1 2020 and held it in 1 quarter.
  • Laurion Capital Management's Agile Therapeutics position peaked at $233K in Q1 2020.
  • 79 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2020.

Based on Laurion Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.